Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Inclusion criteria (Core): * Patients with transfusional iron overload due to: * low or intermediate (INT-1) risk Myelodysplastic Syndrome (MDS)determined via International Prognosis Scoring System (IPSS) criteria * other congenital or acquired anemias excluding B-thalassemia and sickle cell disease * Lifetime transfusion history of ≥20 unit (approximately 100 mL/kg) of packed red blood cells or showing evidence of iron overload (serum ferritin \>1000 µg/L). * Able to provide written informed consent * Life expectancy ≥ 12 months If patient was previously treated with deferiprone, a washout period of one month should occur before the first dose of deferasirox Inclusion criteria (Extension): * Patients completing the planned 12-month core study (CICL670A2204). * Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with national legislation. Exclusion criteria (Core and Extension): * Patients with β-thalassemia, sickle cell disease or myelodysplastic syndrome with an IPSS score being Intermediate-2 or High. * Patients with serum creatinine \> ULN * Patients with ALT(SGPT) levels \> 5 x ULN * Significant proteinuria as indicated by a urinary protein/creatinine ratio \>0.5 mg/mg in a non-first void urine sample on two assessments during the screening period. * History of HIV positive test result , or of clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positi…